神經(jīng)鈣黏蛋白(NCAD)重組蛋白
Recombinant N-cadherin (NCAD)
CDw325; CD325; CDHN; CDH2; Cadherin 2 Type 1; N-Cadherin
- 編號RPB481Ra02
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞膜
- 預測分子量15.0kDa
- 實際分子量19kDa(差異分析請參閱說明書)
- 片段與標簽Ser563~Ser685 (Accession # Q9Z1Y3) with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 97%
- 等電點4.69
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1080 ¥ 2700 ¥ 5400 ¥ 16200 ¥ 40500
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
序列
用法
Reconstitute?in?10mM?PBS?(pH7.4)?to?a?concentration?of?0.1-1.0?mg/mL.?Do?not?vortex
儲存
避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。
增值服務
相關(guān)產(chǎn)品
編號 | 適用物種:Rattus norvegicus (Rat,大鼠) | 應用(僅供研究使用,不用于臨床診斷!) |
RPB481Ra02 | 神經(jīng)鈣黏蛋白(NCAD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB481Ra03 | 神經(jīng)鈣黏蛋白(NCAD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB481Ra01 | 神經(jīng)鈣黏蛋白(NCAD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB481Ra02 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體 | WB; IHC; ICC; IP. |
PAB481Ra03 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體 | WB; IHC; ICC; IP. |
PAB481Ra01 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體 | WB; IHC; ICC; IP. |
LAB481Ra71 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體(生物素標記) | WB; IHC; ICC. |
參考文獻
雜志 | 參考文獻 |
Toxicology Letters | Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. [Pubmed: 23830989] |
British journal of haematology | Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. [Pubmed: 23438504] |
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY | Elevated Cerebrospinal Fluid and Plasma N-Cadherin in Alzheimer Disease [Pubmed: 32296844] |
Cell Biol Toxicol | ZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer [33566221] |
CELL BIOLOGY AND TOXICOLOGY | Metastatic suppression by DOC2B is mediated by inhibition of epithelial-mesenchymal transition and induction of senescence [33758996] |
Pharmacol Res | DOC2B is a Negative Regulator of Wnt/β-catenin Signaling Pathway in Cervical Cancer [Pubmed:35500882] |
留言咨詢